Replies to post #103619 on Biotech Values

[oc631]

I recall the thread well; it does not appear to be directly related to the SAE’s seen in the DDI study.

I tend to agree with you on this but at this point IDX184 can't be ruled out.

two of the three SAE’s cannot be explained by any hypothesis other than an intracellular drug-drug interaction between IDX184 and IDX320

Your hypothesis is a best case scenario for IDIX.

Why do you think the DDI study showed three SAE’s when the prior separate studies of IDX184 and IDX320 in animals and humans did not?

The three day POC study of IDX320 in humans is hardly a fair indicator of future safety. Besides the data set from this study has yet to be released so it seems premature to think otherwise. The two patients that had unexplainable SAE's were those dosed 400mg of IDX320 for 2 weeks. It's quite possible IDX320 may be the problem.